MX2017002476A - Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. - Google Patents
Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.Info
- Publication number
- MX2017002476A MX2017002476A MX2017002476A MX2017002476A MX2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A
- Authority
- MX
- Mexico
- Prior art keywords
- airway
- methods
- extracellular matrix
- fibroblast proliferation
- matrix deposition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 208000000884 Airway Obstruction Diseases 0.000 abstract 2
- 208000036065 Airway Remodeling Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/473,339 US9890200B2 (en) | 2011-04-12 | 2014-08-29 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/047390 WO2016033432A1 (en) | 2014-08-29 | 2015-08-28 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002476A true MX2017002476A (es) | 2017-08-14 |
Family
ID=52583553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002476A MX2017002476A (es) | 2014-08-29 | 2015-08-28 | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890200B2 (enExample) |
| EP (1) | EP3185883A4 (enExample) |
| JP (1) | JP2017528454A (enExample) |
| KR (1) | KR20170044171A (enExample) |
| CN (1) | CN107073075A (enExample) |
| AU (1) | AU2015308761A1 (enExample) |
| BR (1) | BR112017003731A2 (enExample) |
| CA (1) | CA2958085A1 (enExample) |
| MX (1) | MX2017002476A (enExample) |
| RU (1) | RU2017110093A (enExample) |
| SG (1) | SG11201701135WA (enExample) |
| WO (1) | WO2016033432A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| WO2016112292A1 (en) | 2015-01-08 | 2016-07-14 | Moerae Matrix, Inc. | Formulation of mk2 inhibitor peptides |
| JP2018512401A (ja) * | 2015-03-12 | 2018-05-17 | モイライ マトリックス インコーポレイテッド | Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 |
| CN112920256B (zh) * | 2019-11-21 | 2022-08-19 | 上海医药工业研究院 | 一种治疗哮喘的生物肽及其应用 |
| EP4464694A1 (en) | 2022-01-14 | 2024-11-20 | Shanghai Hansoh Biomedical Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| FR2585563B1 (fr) | 1985-07-30 | 1993-11-12 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| EP0672159B1 (en) | 1992-04-24 | 2005-12-28 | Sri International | Homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| WO1995015972A1 (en) | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| MX9603414A (es) * | 1994-02-17 | 1997-03-29 | American Home Prod | Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa. |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| WO2000059476A1 (en) | 1999-04-05 | 2000-10-12 | Pharmaceutical Discovery Corporation | Methods for fine powder formation |
| AU779986B2 (en) | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| KR20110017465A (ko) | 2002-04-25 | 2011-02-21 | 더 스크립스 리서치 인스티튜트 | 폐질환 증상의 치료 및 예방 |
| KR20130001318A (ko) | 2002-07-19 | 2013-01-03 | 애보트 바이오테크놀로지 리미티드 | ＴＮＦα 관련 질환의 치료 |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| EP1937219B1 (en) | 2005-09-14 | 2015-11-11 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| MX2008012794A (es) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Microparticulas de farmacos. |
| EP2155228B1 (en) | 2007-01-10 | 2014-04-02 | Purdue Research Foundation | Polypeptide inhibitors of hsp27 kinase and uses therefor |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| KR20170001756A (ko) | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| CN105920582B (zh) | 2008-12-10 | 2020-04-14 | 普渡研究基金会 | 基于细胞渗透性肽的激酶抑制剂 |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG10201604560TA (en) * | 2011-04-12 | 2016-07-28 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2014
- 2014-08-29 US US14/473,339 patent/US9890200B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 WO PCT/US2015/047390 patent/WO2016033432A1/en not_active Ceased
- 2015-08-28 JP JP2017511933A patent/JP2017528454A/ja active Pending
- 2015-08-28 MX MX2017002476A patent/MX2017002476A/es unknown
- 2015-08-28 BR BR112017003731A patent/BR112017003731A2/pt not_active IP Right Cessation
- 2015-08-28 AU AU2015308761A patent/AU2015308761A1/en not_active Abandoned
- 2015-08-28 EP EP15835631.1A patent/EP3185883A4/en not_active Withdrawn
- 2015-08-28 KR KR1020177007622A patent/KR20170044171A/ko not_active Withdrawn
- 2015-08-28 CN CN201580058532.3A patent/CN107073075A/zh active Pending
- 2015-08-28 RU RU2017110093A patent/RU2017110093A/ru not_active Application Discontinuation
- 2015-08-28 SG SG11201701135WA patent/SG11201701135WA/en unknown
- 2015-08-28 CA CA2958085A patent/CA2958085A1/en not_active Abandoned
-
2017
- 2017-12-27 US US15/855,398 patent/US10562947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20180194817A1 (en) | 2018-07-12 |
| SG11201701135WA (en) | 2017-03-30 |
| KR20170044171A (ko) | 2017-04-24 |
| US10562947B2 (en) | 2020-02-18 |
| JP2017528454A (ja) | 2017-09-28 |
| BR112017003731A2 (pt) | 2017-12-05 |
| RU2017110093A3 (enExample) | 2018-10-01 |
| EP3185883A1 (en) | 2017-07-05 |
| WO2016033432A9 (en) | 2016-04-21 |
| EP3185883A4 (en) | 2018-05-30 |
| CN107073075A (zh) | 2017-08-18 |
| AU2015308761A1 (en) | 2017-02-23 |
| CA2958085A1 (en) | 2016-03-03 |
| RU2017110093A (ru) | 2018-10-01 |
| US20150064134A1 (en) | 2015-03-05 |
| US9890200B2 (en) | 2018-02-13 |
| WO2016033432A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX2025009723A (es) | Metodos de tratamiento contra adicciones | |
| PH12017502087B1 (en) | Tiotropium inhalation solution for nebulization | |
| TN2014000131A1 (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MX2020010738A (es) | Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos). | |
| ZA202001568B (en) | Methods and compositions for treating chronic lung diseases | |
| NZ744942A (en) | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| PH12019500841A1 (en) | Nebulized tiotropium | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. |